CJC-1295 causes the release of GH, but it does so by stimulating the growth hormone releasing hormone receptor. It is also high selective and has demonstrated positive benefits on bone health, lean body mass, insulin resistance, and muscle growth and development. By combining the two peptides, it may be possible to produce enhanced effects because they stimulate the growth hormone axis via two different mechanisms. Research in animal models using both peptides is likely to show increased benefit without substantially increased side effects.
Ipamorelin is one of the most selective growth hormone (GH) secretagogoues known and a potent agonist of the ghrelin/growth hormone secretagogue receptor. It has been heavily researched in a number of settings and is known to, improve bone health, boost muscle repair and development, stimulate insulin release from the pancreas, and improve bowel motility and gastric function.
Ipamorelin is likely to raise baseline levels of GH such that CJC-1295 will be able to produce both high peaks and higher troughs while preserving normal grown hormone pulsatile secretion. The net effect of combining peptides would be a higher set point for the normal ebb and flow of GH, resulting in improved lean body mass, better muscle development, improved use of insulin, and overall better metabolic function.
reactions at injection site, such as pain, redness or swelling along with flushing of the face; and less than 1 percent of patients report dizziness, headache or hyperactivity.
Products are furnished for LABORATORY RESEARCH USE ONLY. This product should only be handled by qualified, and licensed professionals. The product may not be used as a drug, agricultural or pesticide product, food additive, or household chemical – and may not be misbranded as such. All information on this website is available for educational purposes only. Bodily introduction of any kind into humans and/or animals is strictly forbidden by law.